UNSPSC 51313306: Promethazine sulfoxide

This classification denotes a phenothiazine with the molecular formula C17H20N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G44A4PX06U, chemically known as n-(2-(dimethylamino)propyl)phenothiazine s-oxide, but more generally known as promethazine sulfoxide, which bears US NIH Compound Identifier 63032. European Medicines Agency schedules promethazine sulfoxide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10088MIG.

Most nations, for tariff purposes, schedule promethazine sulfoxide under HS 29343090. SMILES: CC(CN1C2CCCCC2[S+](C3C1CCCC3)[O-])N(C)C.

UNSPSC 51313306 Promethazine sulfoxide is a Commodity code that nominally identifies a single pharmaceutical product, yet the recent state and local solicitations posted under it do not involve promethazine sulfoxide directly. Instead, the code appears to capture a broader pharmaceutical procurement pattern in which state and local health and human services agencies acquire multiple medications, drug management systems, and pharmaceutical supply arrangements. The actual work being solicited includes naloxone and drug deactivation systems for community health programs, direct-to-manufacturer prescription fulfillment capabilities, and generic multi-source pharmaceuticals and over-the-counter products supplied through authorized wholesale distributors. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances administered by state procurement offices (Minnesota Department of Administration on behalf of MMCAP, serving multiple states including Oregon). The procurement spans both direct product acquisition and market-intelligence RFIs that precede formal competitive solicitations.

Activity is concentrated in Florida and the Upper Midwest, with the most recent solicitations posted in mid-2026. Seminole County, Florida released IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, due July 26, 2026, as an IFB with a two-year initial term and one-year renewal option. The Texas HHS Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs, posted April 3, 2026 with the same response deadline. The Minnesota Department of Administration, administering MMCAP, posted RFP S1070000015802 in January 2026 seeking generic pharmaceuticals and OTC products from manufacturers to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson), with proposals due March 26, 2026 and contract effectiveness targeted for July 1, 2026. Vendors in both the Seminole County and MMCAP opportunities must maintain specified insurance coverage and comply with federal regulations, including FDA requirements and Drug Supply Chain Security Act certification.